Skip to main content
SpringerLink
Log in

Treatment of Hepatitis C Before Liver Transplantation

  • Chapter
  • First Online:
Hepatitis C Virus and Liver Transplantation

  • 1054 Accesses

Abstract

Hepatitis C recurrence after liver transplantation (LT) is universal and it is characterized by an accelerated course, with 20–30 % of patients developing liver cirrhosis after 5 years of LT. One of the most attractive approaches to prevent hepatitis C recurrence is by treating hepatitis C before transplantation. The aim of this strategy is to prevent the infection of the new graft, either by achieving sustained virological response, or by attaining on treatment response. Nevertheless, the applicability of this strategy is limited by the high risk of severe adverse events associated with interferon-based treatments in patients with liver dysfunction. In the era of protease inhibitors, triple therapy will most likely increase the current rate of viral clearance, even in patients with cirrhosis, but there is still scarcity of data in patients on the waiting list for a LT. Due to the fact that triple therapy includes interferon, only those patients with compensated liver disease have an indication of therapy. Preliminary data obtained in this sub-population suggest a significant increase in the number of haematological side effects, severe infections and decompensations. Therefore, it is mandatory to carefully select patients to be treated before LT. In a few years from now interferon-free regimens combining direct-acting antiviral agents targeting different hepatitis C viral proteins will most likely replace the current treatment and prevent hepatitis C re-infection in most cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–7.

    Article  PubMed  Google Scholar 

  2. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14 Suppl 2:S36–44.

    Article  PubMed  Google Scholar 

  3. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, Carrasco D, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000;32:852–8.

    Article  PubMed  CAS  Google Scholar 

  4. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008;14 Suppl 2:58–66.

    Article  Google Scholar 

  5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.

    Article  PubMed  CAS  Google Scholar 

  6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.

    Article  PubMed  CAS  Google Scholar 

  7. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350–5.

    Article  PubMed  Google Scholar 

  8. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, la Mata M de, Garcia-Valdecasas JC, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389–96.

    Article  PubMed  CAS  Google Scholar 

  9. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255–62.

    Article  PubMed  CAS  Google Scholar 

  10. Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasas JC, Navasa M, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009;50:719–28.

    Article  PubMed  CAS  Google Scholar 

  11. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS Jr, Saab S, Shiffman ML, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology. 2012;57:1752–62.

    Article  Google Scholar 

  12. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007;46:206–12.

    Article  PubMed  CAS  Google Scholar 

  13. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142:1373–83 e1371.

    Article  PubMed  Google Scholar 

  14. Saxena V, Terrault N. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant. 2012;17:216–24.

    Article  PubMed  CAS  Google Scholar 

  15. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, Kundi M, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2011;9:602–8 e601.

    Google Scholar 

  16. Ramirez S, Perez-Del-Pulgar S, Carrion JA, Costa J, Gonzalez P, Massaguer A, Fondevila C, et al. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant. 2009;9:1591–601.

    Article  PubMed  CAS  Google Scholar 

  17. Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opin Pharmacother. 2009;10:1929–38.

    Article  PubMed  CAS  Google Scholar 

  18. Rincon D, Ripoll C, Lo Iacono O, Salcedo M, Catalina MV, Alvarez E, Nunez O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol. 2006;101:2269–74.

    Article  PubMed  CAS  Google Scholar 

  19. Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, Angus P. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5:932–7.

    Article  PubMed  Google Scholar 

  20. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–87.

    Article  PubMed  CAS  Google Scholar 

  21. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–84.

    Article  PubMed  Google Scholar 

  22. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.

    Article  PubMed  Google Scholar 

  23. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.

    Article  PubMed  CAS  Google Scholar 

  24. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–24.

    Article  PubMed  CAS  Google Scholar 

  25. Product Information. Incivek (Telaprevir). Cambridge: Vertex Pharmaceuticals Incorporated; 2011.

    Google Scholar 

  26. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.

    Article  PubMed  CAS  Google Scholar 

  27. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.

    Article  PubMed  CAS  Google Scholar 

  28. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.

    Article  PubMed  CAS  Google Scholar 

  29. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic) – nct01514890. J Hepatol 2013;2013 May 10. pii: S0168–8278(13)00290–0. doi: 10.1016/j.jhep.2013.04.035. [Epub ahead of print].

    Google Scholar 

  30. Fontaine H, Hezode C, Dorival C, Larrey D, Zoulim F, De Ledinghen V, Canva V, et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the french early access pregram (ANRS CO20-CUPIC). J Hepatol. 2013;58:27.

    Article  Google Scholar 

  31. Verna EC, Terry N, Lukose T, Mentore K, Olsen SK, Fox AN, Satoskar R, et al. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV-infected patients awaiting liver transplantation. Hepatology. 2012;56:218A.

    Google Scholar 

  32. Gallegos-Orozco JF, Chervenak AE, Carey EJ, Aqel B, Byrne TJ, Hartel LA, Rakela J, et al. Liver transplant center focused experience with peginterferon alfa-2a, ribavirin and telaprevir therapy in patients with genotype 1 hepatitis C cirrhosis. Hepatology. 2012;2012:218A.

    Google Scholar 

  33. Soriano V, Gane EJ, Angus P, Stickel F, Bronowicki JP, Roberts S, Manns MP, et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 ± ribavirin (RBV) in treatment-naïve patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: Results from the SOUND-C2 study (Abstract). Hepatology. 2012;56:234A.

    Google Scholar 

  34. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, et al. Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. N Engl J Med. 2013;368:1878–87.

    Article  PubMed  CAS  Google Scholar 

  35. Jacobson IM, Yoshida EM, Sulkowski MS, Nelson DR, Svarovskaia E, An D, McNally J, et al. Treatment with sofosbuvir + ribavirin for 12 weeks achieves SVR12 of 78 % in G2/3 interferon-ineligible, -intolerant, or -unwilling: results of the pahse 3 positron trial (Abstract). J Hepatol. 2013;58:28.

    Article  Google Scholar 

  36. Kowdley K, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99 % in treatment-naïve patients and 93 % in prior null responders with HCV genotype1 infection. (LB Abstract). AASLD 2012.

    Google Scholar 

  37. Kathri A, Menon R, Awni WM, Dutta S. Pharmacokinetics and Safety of Co-administered ABT-450 plus Ritonavir (ABT-450/r), ABT-267 and ABT-333 as a Single Dose in Subjects with Normal Hepatic Function and in Subjects with Mild, Moderate and Severe Hepatic Impairment. Hepatology. 2012;56:555A.

    Google Scholar 

  38. Ferenci P, Scherzer TM, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schoniger-Hekele M, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561–7.

    Article  PubMed  CAS  Google Scholar 

  39. Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J Hepatol. 2012;56:1019–24.

    Article  PubMed  CAS  Google Scholar 

  40. Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J Hepatol. 2010;52:951–2.

    Article  PubMed  CAS  Google Scholar 

  41. Mariño Z, Crespo G, D’Amato M, Brambilla N, Giacovelli G, Rovati L, Costa J, et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol. 2012;58:415–20.

    Article  PubMed  Google Scholar 

  42. Barcena R, Moreno A, Rodriguez-Gandia MA, Albillos A, Arocena C, Blesa C, Garcia-Hoz F, et al. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol. 2012;58:421–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Unit, IMDM, Institut de Investigacions Biomèdiques Pi I Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Hospital Clinic, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain

    Maria-Carlota Londoño MD, PhD & Xavier Forns MD, PhD

Authors
  1. Maria-Carlota Londoño MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Forns MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Forns MD, PhD .

Editor information

Editors and Affiliations

  1. La Fe Hospital, University of Valencia and Ciberehd, Valencia, Spain

    Marina Berenguer

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Londoño, MC., Forns, X. (2014). Treatment of Hepatitis C Before Liver Transplantation. In: Berenguer, M. (eds) Hepatitis C Virus and Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8438-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8438-7_1

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8437-0

  • Online ISBN: 978-1-4614-8438-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation